白蛋白结合型紫杉醇二线治疗骨肉瘤肺转移的临床观察  

Clinical observation of albumin-bound paclitaxel in the treatment of osteosarcoma with lung metastasis

作　　者：牛晓辉[1] 杨勇昆[1] 黄真[1] 徐海荣[1] 

机构地区：[1]北京积水潭医院骨肿瘤科,北京100035

出　　处：《临床肿瘤学杂志》2013年第2期114-116,共3页Chinese Clinical Oncology

基　　金：首都医学发展科研基金资助项目(2009-3096)

摘　　要：目的探讨白蛋白结合型紫杉醇二线治疗一线化疗失败的骨肉瘤肺转移患者的疗效和安全性。方法收集19例一线化疗失败的骨肉瘤肺转移患者,均予白蛋白结合型紫杉醇125～140mg/m2静滴,d1、d8。21天为1个周期。采用RECIST 1.0标准评价疗效,NCI-CTC 3.0标准评价不良反应。结果 19例患者均可评价疗效。无CR病例,获PR 1例,SD 5例,PD 13例;总有效率(RR)为5.3%,疾病控制率(DCR)为31.6%;中位无疾病进展时间(PFS)为2.2个月。仅2例患者发生1级白细胞减少,未发生其他不良反应。结论对于一线化疗失败的骨肉瘤肺转移患者,使用白蛋白结合型紫杉醇治疗安全性良好,并取得一定疗效。Objective To evaluate the efficacy and adverse effects of albumin-bound paclitaxel as the second-line treatment for osteosarcoma with lung metastasis. Methods Nineteen osteosarcoma patients with lung metastasis failed with first-line chemothera- py were received albumin-bound paclitaxel（ 125-140mg/m2iv d1, d8 ）. Twenty-one days were regarded as a cycle. The efficacy was as- sessed according to RECIST 1.0 standard and adverse effect was evaluated by NCI-CTC 3.0 standard. Results The efficacy of 19 pa- tients could be evaluated. No case achieved CR, with 1 PR, 5 SD and 13 PD. The disease control rate was 31.6% , and the response rate was 5.3%. The median progression free survival was 2. 2 months. The adverse effect was grade one leucopenia in two cases, and other adverse effects were not observed. Conclusion Albumin-bound paclitaxel as the second-line treatment for osteosarcoma patients with lung metastasis is effective and well-tolerated.

关 键 词：骨肉瘤 肺转移 化学治疗 白蛋白结合型紫杉醇 

分 类 号：R738.1[医药卫生—肿瘤]